Enrollment has been wrapped up in a large, worldwide, late-stage clinical trial that’s testing the therapy candidate zorevunersen for reducing seizures in children and teens with Dravet syndrome. According to developer Stoke Therapeutics, which is sponsoring the Phase 3 study, October marked the completion of recruitment of…
News
Two children with Dravet syndrome developed severe toxicity from the anti-seizure medicine valproic acid after stopping the ketogenic diet, a case study reported. The study, the first to report the issue, showed that the diet suppressed valproic acid blood levels in both children, which rose sharply once the diet…
Children with Dravet syndrome experience developmental and language delays, but the nature and severity of their communication difficulties can vary widely, a small study in Spain suggests. All six children in the study showed delays in language development, but their ability to understand and use language varied considerably. Some had…
High temperatures and heat waves may make seizures more frequent, longer-lasting, and harder to manage in children and adolescents with Dravet syndrome, according to parents interviewed in a new study. Parents described summer heat as a persistent seizure trigger that could dramatically change their children’s seizure patterns and force…
Stoke Therapeutics says it’s aligned with the U.S. Food and Drug Administration (FDA) on key aspects of a planned application seeking approval of zorevunersen for Dravet syndrome — including how to analyze data from an ongoing Phase 3 clinical trial testing the potential anti-seizure med. According to…
Treatment with cannabidiol (CBD) can help reduce the frequency of seizures for some adults with Dravet syndrome and other forms of childhood-onset epilepsy, a study showed. The study reported data from 37 adults with epilepsy who underwent CBD treatment at three medical centers in Spain. After one year of…
Fintepla (fenfluramine) — either alone or as an add-on to Diacomit (stiripentol) — was associated with fewer seizures in a small group of young patients with Dravet syndrome, a study from Italy found. The results also suggested that starting treatment earlier may offer cognitive and motor benefits.
Treatment with the approved Dravet syndrome drug Fintepla (fenfluramine) was more effective than a placebo at reducing seizure frequency and extending periods without seizures among a diverse group of children and adolescents with the rare disease, data from three late-stage clinical trials show. The oral therapy, widely cleared…
Encoded Therapeutics has raised $275 million in Series F financing to support the clinical development of its experimental gene therapy ETX101 for infants and young children with Dravet syndrome. The funds will also support an expansion study in children and adolescents up to age 18, and the commercial…
Treatment with the experimental therapy zorevunersen may alter the progression of Dravet syndrome, according to new long-term data from early clinical trials. The data indicate that zorevunersen led to long-term reductions in seizure rates, improved communication abilities, and overall quality of life, and that the experimental treatment was generally…
Recent Posts
- The joy and burden of being my daughter’s primary caregiver
- Trial testing Dravet treatment enrolls children in US, Europe, China
- I worry about how puberty might affect my daughter’s seizures
- Stopping keto diet triggers drug toxicity in 2 Dravet kids, report says
- For me, IEP meetings for my daughter are uniquely uncomfortable